



Disclaimer

The information in this presentation has been reviewed and approved for public dissemination in accordance with U.S. Environmental Protection Agency (EPA). The views expressed in this presentation are those of the author(s) and do not necessarily represent the views or policies of the Agency. Any mention of trade names or commercial products does not constitute EPA endorsement or recommendation for use.



Classification model of blood-brain barrier development and toxicity

Katerine S. Saili, Todd J. Zurlinden, Thomas B. Knudsen


National Center for Computational Toxicology
Office of Research and Development
Research Triangle Park, NC

Horizons and Challenges in Organotypic Culture Models for Predictive Toxicology
Society of Toxicology Satellite Session
March 11, 2017





The views expressed in this presentation are those of the authors and may not reflect U.S. EPA policy

U.S. Environmental Protection Agency





Neurovascular unit (NVU)

Hypothesis: Chemical disruption of NVU development will adversely impact blood-brain barrier (BBB) formation, and lead to abnormal brain development and function



Biowiring diagram of NVU development



- **Objective:**

- Identify putative biomarkers of developmental NVU disruption among ToxCast HTS assays
- Build a pathway based predictive signature to identify putative NVU disrupting ToxCast chemicals (Neuro, Angio, both, or neither)

- **Approach:** Increase the diversity of ToxCast assays to include DevTox assessments that may represent developmental processes or toxicities


- ArunA (neurogenic), Vala (angiogenic), STEMINA (hESC), OT (endogenesis)

NVU

Early development



Experimental Design

Exposures: 0.1% DMSO control
0.1 - 100 μ M (x5 concentrations)




46 ToxCast chemicals

- 5HPP-33 (ref.)
- TNP-470 (ref.)
- flame retardants
- pesticides
- pharmaceuticals
- plasticizers
- pTDCs
- pVDCs

Platform	Cell type	Assay	# of Endpoints	
	Neurogenesis hESC (H9)	{ <ul style="list-style-type: none"> hNP hNC hNN 	{ <ul style="list-style-type: none"> Cell titer Cell migration/proliferation Neurite outgrowth 	2 2 4
	Angiogenesis HUVEC (iPSC)	{ <ul style="list-style-type: none"> Tubule formation agonist Tubule formation antagonist Cell migration/proliferation 	1 1 3	

Positive 'hits' across 13 assays




ToxPi ranking of 46 Aruna/Vala chemicals

Angio
X9




Neurogenesis
Assays x8



Angiogenesis
Assays x5



No Effect
x8



AC₂₀ normalized to control
shown as percentage of max
potency across all assays


Building a pathway-based prediction model of NVU toxicity

ToxCast assays



10
cals

Identifying signaling pathways that may mediate toxic effects on the NVU



413 ToxCast assays
(assay_component_endpoint_name)





194 associated genes
(tech_target)



KEGG pathway analysis





Angiogenesis and/or neurogenesis




Signaling pathways that may mediate toxic effects on the NVU

Neurogenesis




Angiogenesis and neurogenesis



AGE-RAGE signaling pathway in diabetic complications (20.64)


Serotonergic synapse (15.71)

Bladder cancer (14.87)



Top Pathway – Top Chemical

Hypothesis: Chemical disruption of NVU development will adversely impact blood-brain barrier (BBB) formation, and lead to abnormal brain development and function



Obermeier et al., *Nat Meth.* 2013

AGE-RAGE signaling pathway
in diabetic complications

Immune response	Adhesion	Cell growth/survival	Coagulation	ECM remodeling
CCL2	SELE	JUN	F3	MMP2
CXCL8	VCAM1	PI3CA	THBD	
IL6	ICAM1	MAPK1		
TNF				
TGFB1				
NFKB1				

(genes from list in pathway)


5HPP-33 gene targets based on ToxCast assay hits

Future work

- Focus on role of microglia
 - Cell transducers of inflammatory signals
 - Role in remodeling/anastomosis during angiogenesis
- Test more ToxCast chemicals in these platforms
- Prioritize chemicals for OCM *in vitro* testing

Acknowledgements

- Tom Knudsen (mentor)
- Todd Zurlinden (NCCT)
- Sid Hunter (NHEERL-ISTD)
- Andrew Schwab (NHEERL-ISTD)
- Nancy Baker (Leidos)
- Virtual Tissue Modeling Group
- Florent Ginhoux (A*STAR)
- Aymeric Silvan (A*STAR)
- Dan Rines (Vala Sciences)
- Bei Bei Cai (Vala Sciences)
- Steve Stice (Aruna Biomedical)
- Tracey Worthington Stice (Aruna Biomedical)





Thank You

Questions?